Adult Patients Undergoing CABGNCT07271615
Effect of Preoperative Stellate Ganglion Block on Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting
A study testing Stellate Ganglion Block in people with Adult Patients Undergoing CABG, run by Xijing Hospital at 1 site in China.
Trial summary
The primary objective of this study is to determine the feasibility of preoperative stellate ganglion block in reducing the incidence of postoperative atrial fibrillation in patients undergoing CABG. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Adult Patients Undergoing CABG
- What is being tested?
- Stellate Ganglion Block
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteChina
- Study dates
- 19 Nov 2025to 31 Jul 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- more than 18 years old
- undergoing CABG
- Provide informed consent
Who cannot join
- History of prior cardiac surgery or atrial fibrillation ablation;
- Emergency coronary artery bypass grafting (CABG);
- Concomitant cardiac procedures (e.g., congenital heart disease repair, left ventricular reconstruction, valve surgery, or aortic surgery);
- Critical preoperative status requiring mechanical or pharmacological support before CABG;
- Left ventricular ejection fraction (LVEF) <35%;
- History of atrial fibrillation (defined as a supraventricular tachyarrhythmia characterized by rapid and irregular atrial electrical activity);
Show all 11Show fewer
- Significant mitral valve disease (mitral valve area <1.5 cm² or regurgitant jet area <4 cm²), significant aortic valve disease (valve area <1.5 cm² or regurgitant jet-to-left ventricular outflow tract ratio >25%);
- Severe left atrial enlargement (left atrial anteroposterior diameter >55 mm);
- Poorly controlled hyperthyroidism;
- Conditions requiring radiotherapy, chemotherapy, or long-term hormonal therapy;
- Patients with known clinical contraindications to stellate ganglion block (SGB).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Preoperative Stellate Ganglion Block Reduce the Incidence of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Prospective, Randomized Controlled Pilot Trial
The primary objective of this study is to determine the feasibility of preoperative stellate ganglion block in reducing the incidence of postoperative atrial fibrillation in patients undergoing CABG.
- Conditions
- Adult Patients Undergoing CABG
- Being tested
- Stellate Ganglion Block
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Stellate Ganglion BlockProcedure or surgery
Ultrasound-guided stellate ganglion block with ropivacaine
| Study group | Role | What they receive |
|---|---|---|
| Control group（C group） | No intervention | the best available treatment without block (usual care) |
| Stellate Ganglion Block（S group） | Other | Ultrasound-guided stellate ganglion block with ropivacaine Receives: Procedure: Stellate Ganglion Block |
What is being measured
The primary outcome is the main question the study is designed to answer.
postoperative atrial fibrillation（POAF）
Measured: within 7 days postoperatively
Secondary outcomes (6)
cumulative time spent in postoperative atrial fibrillation
Measured: within 7 days postoperatively
the need for antiarrhythmic medications to treat postoperative atrial fibrillation
Measured: within 7 days postoperatively
the need for systemic anticoagulation due to postoperative atrial fibrillation
Measured: within 7 days postoperatively
the need for postoperative electrical cardioversion
Measured: within 7 days postoperatively
the duration of postoperative in-hospital stay
Measured: duration of postoperative hospital stay
number of POAF
Measured: within 7 days postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2025
- Study start19 Nov 2025
- Primary completion31 May 2026
- Study completion31 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adult Patients Undergoing CABGStudies of the same condition, open and under way.
- More trials run by Xijing HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Xijing Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chong Lei, MD & phD, Xijing Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07271615
- Sponsor's protocol ID
- KY20250716
- Status last verified
- Aug 2026
- First submitted
- 26 Nov 2025
- Last updated
- 4 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Preoperative Stellate Ganglion Block Reduce the Incidence of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Prospective, Randomized Controlled Pilot Trial
- ClinicalTrials.gov ID
- NCT07271615
- Acronym / sponsor ID
- KY20250716
- Conditions
- Adult Patients Undergoing CABG
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Xijing HospitalUniversity, hospital or other
- Study start
- 19 Nov 2025 (actual)
- Primary completion
- 31 May 2026 (actual)
- Study completion
- 31 Jul 2026 (actual)
- First posted
- 9 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to determine the feasibility of preoperative stellate ganglion block in reducing the incidence of postoperative atrial fibrillation in patients undergoing CABG.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control group（C group） | No intervention | –the best available treatment without block (usual care) |
| Stellate Ganglion Block（S group） | Other | Procedure: Stellate Ganglion BlockUltrasound-guided stellate ganglion block with ropivacaine |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- more than 18 years old
- undergoing CABG
- Provide informed consent
Key exclusion criteria (11 listed)
- History of prior cardiac surgery or atrial fibrillation ablation;
- Emergency coronary artery bypass grafting (CABG);
- Concomitant cardiac procedures (e.g., congenital heart disease repair, left ventricular reconstruction, valve surgery, or aortic surgery);
- Critical preoperative status requiring mechanical or pharmacological support before CABG;
- Left ventricular ejection fraction (LVEF) <35%;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Stellate Ganglion BlockUltrasound-guided stellate ganglion block with ropivacaine | Procedure or surgery | Stellate Ganglion Block（S group） |
Primary outcome
postoperative atrial fibrillation（POAF）
Time frame: within 7 days postoperatively
6 secondary outcomes
cumulative time spent in postoperative atrial fibrillation
Time frame: within 7 days postoperatively
the need for antiarrhythmic medications to treat postoperative atrial fibrillation
Time frame: within 7 days postoperatively
the need for systemic anticoagulation due to postoperative atrial fibrillation
Time frame: within 7 days postoperatively
the need for postoperative electrical cardioversion
Time frame: within 7 days postoperatively
the duration of postoperative in-hospital stay
Time frame: duration of postoperative hospital stay
number of POAF
Time frame: within 7 days postoperatively
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Aug 2026.
Related trials for Adult Patients Undergoing CABG
Not yet recruitingObservational study
Preoperative Gastric Ultrasound and Anaesthetic Management in Patients Undergoing Coronary Artery Bypass Grafting
Preoperative Fasting, Pulmonary Aspiration During Anesthetic Induction
RecruitingPhase 4
Adding Lidocaine to Custodiol Mixture
CAD, Arrhythmia Ventricular
Not yet recruitingPhase 1/2
HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery
Advanced Heart Failure, Ischemic Heart Failure
Not yet recruiting
Effect of Preoperative Sleep Intervention on Postoperative Delirium in Adult Patients Undergoing Cardiac Surgery
Delirium - Postoperative, Sleep Problems
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Stellate Ganglion Block in people with Adult Patients Undergoing CABG, run by Xijing Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
postoperative atrial fibrillation（POAF） (time frame: within 7 days postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2026.